Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GHRS NASDAQ:MGTX NASDAQ:SAVA NASDAQ:SNDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHRSGH Research$13.37+1.5%$13.21$6.58▼$20.50$693.56M0.97323,591 shs134,435 shsMGTXMeiraGTx$8.65+4.7%$7.83$3.97▼$8.98$696.30M1.34496,764 shs154,225 shsSAVACassava Sciences$4.08+2.4%$2.49$1.15▼$33.98$197.83M-0.981.76 million shs2.08 million shsSNDLSNDL$2.80+6.3%$2.32$1.15▼$2.89$734.47M3.832.48 million shs4.92 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHRSGH Research+0.61%-2.95%-2.52%-17.94%+104.50%MGTXMeiraGTx-2.71%-0.12%+10.58%-4.18%+99.04%SAVACassava Sciences+16.37%+24.38%+85.98%+84.26%-84.72%SNDLSNDL-0.75%+3.54%+10.04%+85.21%+35.57%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHRSGH Research$13.37+1.5%$13.21$6.58▼$20.50$693.56M0.97323,591 shs134,435 shsMGTXMeiraGTx$8.65+4.7%$7.83$3.97▼$8.98$696.30M1.34496,764 shs154,225 shsSAVACassava Sciences$4.08+2.4%$2.49$1.15▼$33.98$197.83M-0.981.76 million shs2.08 million shsSNDLSNDL$2.80+6.3%$2.32$1.15▼$2.89$734.47M3.832.48 million shs4.92 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHRSGH Research+0.61%-2.95%-2.52%-17.94%+104.50%MGTXMeiraGTx-2.71%-0.12%+10.58%-4.18%+99.04%SAVACassava Sciences+16.37%+24.38%+85.98%+84.26%-84.72%SNDLSNDL-0.75%+3.54%+10.04%+85.21%+35.57%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHRSGH Research 2.67Moderate Buy$32.00139.41% UpsideMGTXMeiraGTx 2.33Hold$24.00177.49% UpsideSAVACassava Sciences 1.50Reduce$2.00-50.92% DownsideSNDLSNDL 2.00Hold$4.5061.00% UpsideCurrent Analyst Ratings BreakdownLatest SAVA, GHRS, MGTX, and SNDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025GHRSGH ResearchWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MGTXMeiraGTxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SAVACassava SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SNDLSNDLWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GHRSGH ResearchWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MGTXMeiraGTxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SAVACassava SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SNDLSNDLWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/3/2025SNDLSNDLAlliance Global PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$5.008/15/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.008/13/2025GHRSGH ResearchZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 10/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHRSGH ResearchN/AN/AN/AN/A$3.44 per shareN/AMGTXMeiraGTx$33.28M20.91N/AN/A$0.87 per share9.94SAVACassava SciencesN/AN/AN/AN/A$3.03 per shareN/ASNDLSNDL$671.81M1.09N/AN/A$3.15 per share0.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHRSGH Research-$38.96M-$0.74N/AN/AN/AN/A-16.71%-16.06%11/13/2025 (Estimated)MGTXMeiraGTx-$147.79M-$2.04N/A22.76N/A-415.39%-314.44%-63.28%11/12/2025 (Estimated)SAVACassava Sciences-$24.34M-$2.55N/AN/AN/AN/A-66.16%-53.11%11/6/2025 (Estimated)SNDLSNDL-$69.18M-$0.27N/AN/AN/A-10.38%-8.58%-7.23%11/4/2025 (Estimated)Latest SAVA, GHRS, MGTX, and SNDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MGTXMeiraGTx-$0.52-$0.48+$0.04-$0.48$8.00 million$3.69 million8/14/2025Q2 2025SAVACassava SciencesN/A-$0.18N/A-$0.92N/AN/A8/7/2025Q2 2025GHRSGH Research-$0.22-$0.15+$0.07-$0.15N/AN/A7/31/2025Q2 2025SNDLSNDL-$0.04$0.01+$0.05$0.01$231.50 million$179.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHRSGH ResearchN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/ASNDLSNDLN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHRSGH ResearchN/A29.4929.49MGTXMeiraGTx26.290.880.88SAVACassava SciencesN/A2.432.43SNDLSNDL0.115.033.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHRSGH Research56.90%MGTXMeiraGTx67.48%SAVACassava Sciences38.05%SNDLSNDLN/AInsider OwnershipCompanyInsider OwnershipGHRSGH Research41.60%MGTXMeiraGTx7.50%SAVACassava Sciences2.40%SNDLSNDLN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHRSGH Research1052.03 million30.38 millionOptionableMGTXMeiraGTx30080.45 million74.41 millionOptionableSAVACassava Sciences3048.31 million47.15 millionOptionableSNDLSNDL2,516262.78 millionN/AOptionableSAVA, GHRS, MGTX, and SNDL HeadlinesRecent News About These CompaniesSNDL's (SNDL) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 9 at 2:39 AM | marketbeat.comSNDL (NASDAQ:SNDL) Trading Up 5.3% - Here's WhyOctober 7 at 12:47 PM | marketbeat.comSNDL (NASDAQ:SNDL) Downgraded to Hold Rating by Wall Street ZenOctober 4, 2025 | marketbeat.comSNDL (NASDAQ:SNDL) Sets New 1-Year High Following Analyst UpgradeSeptember 30, 2025 | americanbankingnews.comMarket-Beating SNDL Inc. (SNDL) Attracts Stake Boost From Goldman SachsSeptember 29, 2025 | msn.comSNDL (NASDAQ:SNDL) Reaches New 1-Year High Following Analyst UpgradeSeptember 29, 2025 | marketbeat.comSNDL (NASDAQ:SNDL) Rating Increased to Buy at Wall Street ZenSeptember 28, 2025 | americanbankingnews.comSNDL (NASDAQ:SNDL) Stock Rating Upgraded by Wall Street ZenSeptember 26, 2025 | marketbeat.comSNDL (NASDAQ:SNDL) Trading Down 4.7% - Here's WhySeptember 26, 2025 | marketbeat.comBest Cannabis Stocks in Canada to Watch Now: Technical Signals and Market OutlookSeptember 18, 2025 | marijuanastocks.comMSNDL Releases Second Quarter 2025 Financial and Operational ResultsSeptember 16, 2025 | insidermonkey.comSNDL Is Up Too MuchSeptember 14, 2025 | seekingalpha.com3 Marijuana Stocks For Better Gains This MonthSeptember 12, 2025 | marijuanastocks.comMThe Best Cheap Stocks Under $10 to BuySeptember 10, 2025 | zacks.comAlliance Global Partners Initiates Coverage of SNDL (SNDL) with Buy RecommendationSeptember 4, 2025 | msn.comSNDL initiated with a Buy at Alliance Global PartnersSeptember 3, 2025 | msn.comMichigan Cannabis Retailer Case Ruling Codifies Receiver PowerAugust 29, 2025 | news.bloomberglaw.comNHow’s the Market Reacting to SNDL Inc’s (SNDL) Q2 Results?August 29, 2025 | finance.yahoo.comWhat Makes SNDL Inc. (SNDL) a Strong Momentum Stock: Buy Now?August 27, 2025 | zacks.comSNDL Inc. (SNDL)'s Technical Outlook is Bright After Key Golden CrossAugust 27, 2025 | zacks.comDespite Fast-paced Momentum, SNDL INC (SNDL) Is Still a ... - NasdaqAugust 23, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSAVA, GHRS, MGTX, and SNDL Company DescriptionsGH Research NASDAQ:GHRS$13.37 +0.20 (+1.49%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.MeiraGTx NASDAQ:MGTX$8.65 +0.39 (+4.71%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Cassava Sciences NASDAQ:SAVA$4.08 +0.10 (+2.39%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.SNDL NASDAQ:SNDL$2.80 +0.17 (+6.27%) As of 11:38 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
